Uterine Neoplasms

168 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Neoplasms

Narrower: Endometrial Neoplasms 100, Uterine Cervical Neoplasms 66

Treatments and conditions

Uterine Neoplasms
Treatment and conditionWhere it standsTrials
Adaptive Hypofractionated Radiotherapy for endometrial neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Adaptive Hypofractionated Radiotherapy for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Adebelimab Combined with Apatinib for endometrial neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Adebrelimab for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
AdHER2DC vaccine + PATHWAY HER2 (4B5) assay + Nogapendekin Alfa Inbakicept + PEMBROLIZUMAB + LENVATINIB for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AdHER2DC vaccine + PATHWAY HER2 (4B5) assay + PEMBROLIZUMAB + LENVATINIB for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AK105 and anlotinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Anti-PD-1 monoclonal antibody + LCB84 for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Anti-PD-1 monoclonal antibody + LCB84 for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
anti-PD1 agent therapy - 1 year for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
anti-PD1 agent therapy - 2 years for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Atezolizumab for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Avelumab for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Axitinib + AVELUMAB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD8205 and AZD2936 (Rilvegostomig) for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD8205 and AZD5305 (saruparib) + AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig) for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD8205 in combination with AZD9574 + AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936) for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azenosertib for uterine neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
B1962 for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
BEVACIZUMAB + PEMBROLIZUMAB + Izalontamab Brengitecan for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BEVACIZUMAB + PEMBROLIZUMAB + Izalontamab Brengitecan for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BNT329 for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BNT329 + CA19-9-targeting monoclonal antibody for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Brachytherapy + External Beam Radiotherapy (EBRT) + NIMOTUZUMAB + CISPLATIN for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Brachytherapy + External Beam Radiotherapy (EBRT) + placebo for Nimotuzumab + CISPLATIN for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Cadonilimab for uterine cervical neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cadonilimab + lenvatinib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
camrelizumab; famitinib malate for uterine cervical neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
capecitabine or 5-FU + Intensity Modulated Radiation Therapy (IMRT) + DOSTARLIMAB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Capivasertib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Capivasertib for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + NAB-PACLITAXEL for uterine cervical neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + PEMBROLIZUMAB + CISPLATIN + Sigvotatug Vedotin for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + PEMBROLIZUMAB + Sigvotatug Vedotin for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin-Paclitaxel for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] + CEMIPLIMAB + Ubletamig for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Chemotherapy + FAMITINIB L-MALATE + CAMRELIZUMAB for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Chemotherapy + Hypofractionated external beam radiation + Image-guided brachytherapy for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
concurrent chemotherapy + Definitive hypofractionated intensity-modulated radiation theraphy for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CR-002 for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Daraxonrasib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dexamethasone + Prednisolone + FARLETUZUMAB ECTERIBULIN + Prednisone for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Diane-35 + N-METHYL-N-ETHYLTRYPTAMINE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dostarlimab for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI] for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elironrasib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elironrasib + Daraxonrasib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ETX-19477 for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Farletuzumab ecteribulin for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + Tersolisib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + Tersolisib for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Gecacitinib + ZG005 + BEVACIZUMAB for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Glucagon-like peptide 1 receptor agonist for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GnRH agonist and Letrozole + Megestrol + MEDROXYPROGESTERONE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GnRHa + Letrozole for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GT101 + HUMAN INTERLEUKIN-2 for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
High Dose Rate Brachytherapy + intra-lesional boost IMRT for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Iparomlimab and Tuvonralimab (QL1706) for endometrial neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
JSKN033 + BEVACIZUMAB + PLATINUM for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
LCB84 for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
LCB84 for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lenvatinib + farletuzumab ecteribulin for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lorigerlimab for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + AFATINIB + AFATINIB DIMALEATE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mazdutide for endometrial neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Observation for endometrial neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Olaparib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Olomorasib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Olomorasib + PEMBROLIZUMAB + Cetuximab for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OncoSignature + Prexasertib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
OncoSignature + Prexasertib + Gemcitabine for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
paclitaxel combined with platinum for uterine cervical neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Patritumab Deruxtecan for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Patritumab Deruxtecan for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pembrolizumab for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pembrolizumab + nesuparib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pemetrexed + Carboplatin + Olomorasib + PEMBROLIZUMAB + Cetuximab + CISPLATIN for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prexasertib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prexasertib + Gemcitabine for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Puxitatug Samrotecan for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
radical surgery + CAMRELIZUMAB + Paclitaxel + CISPLATIN for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rescue medications + Sacituzumab tirumotecan for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab + cisplatin for uterine neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab govitecan for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab govitecan for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Sacituzumab tirumotecan for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab tirumotecan for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Serplulimab for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
SHR-A1811 Injection for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sigvotatug Vedotin for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sintilimab for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
SINTILIMAB + Megestrol + MEDROXYPROGESTERONE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sirolimus for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Talazoparib + avelumab for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tersolisib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tersolisib for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Topotecan + toripalimab for endometrial neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Trastuzumab deruxtecan for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
TRASTUZUMAB DERUXTECAN + Rilvegostomig for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tretinoin for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tretinoin for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
UBAMATAMAB + Ubletamig + SARILUMAB for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VLS-1488 for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vudalimab for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vudalimab for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.